The effect of K-582, a new antifungal agent, on experimental Candida keratitis.
K-582, a new basic peptide antibiotic, was tested in rabbits with experimental Candida keratitis. It was shown that the K-582-treated group showed statistically highly significant therapeutic effects on days 2 and 3, as compared with the control group (day 2: P less than 0.001; day 3: P less than 0.001). The culture study showed that the average number of colonies was 1,573.1 in the controls and 463.3 in the treated group, and the difference was highly significant statistically (P less than 0.001). No ocular or systemic toxic effects were observed with this drug. K-582 is a promising new drug for the treatment of Candida keratitis.
D000818:Animals; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; D010455:Peptides; C026530:myroridin K